Curative Diagnostics

Curative Diagnostics specializes in disposable autoinjector needles, specifically designed for insulin pens. Their primary product line includes devices like the Overt Insulin Pen Needles, which are intended for subcutaneous insulin administration in diabetes management. These needles are part of a broader category of devices used to facilitate precise and user-friendly insulin delivery.

Curative Diagnostics is headquartered in the United States. The company’s location is relevant for understanding regulatory oversight, as it operates under the jurisdiction of the U.S. Food and Drug Administration (FDA). This positioning also influences compliance with U.S. medical device regulations and reporting requirements.

Curative Diagnostics’ devices are listed in the FDA’s Unique Device Identifier (UDI) database. The UDI system is a standardized approach to identify medical devices throughout their distribution and helps ensure traceability, transparency, and regulatory compliance. This listing is critical for tracking devices like their Overt Insulin Pen Needles in clinical and commercial settings.

Curative Diagnostics’ devices, such as their Overt Insulin Pen Needles, are classified as FDA Class II medical devices. This classification is determined based on the level of risk associated with the device. Class II devices generally require special controls in addition to general controls to ensure their safety and effectiveness, which may include performance standards, post-market surveillance, or labeling requirements.